EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain

On Tuesday, the Israeli Ministry of Health and the Institutional Review Board (IRB) approved MIRA Pharmaceuticals, Inc.’s (NASDAQ:MIRA) Phase 1 trial for Ketamir-2, the company’s novel oral ketamine analog in development for neuropathic pain.

In December, MIRA Pharmaceuticals submitted an Investigational New Drug (IND) application to the FDA to start human trials for Ketamir-2.

MIRA’s preclinical studies demonstrate Ketamir-2’s superior efficacy, safety, and optimized pharmacokinetics, supporting its advancement into Phase 1 clinical trials.

Also Read: EXCLUSIVE: MIRA Pharmaceuticals Validates Ketamir-2’s Safety Profile, Paving Way For Human Trials In Neuropathic Pain

Subject recruitment is scheduled to begin in the first quarter of …

Full story available on Benzinga.com